Page 31 - Read Online

Fujimoto et al. J Cancer Metastasis Treat 2021;7:66 https://dx.doi.org/10.20517/2394-4722.2021.157 Page 13 of 14

newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget 2016;7:29092-101. DOI
PubMed PMC
52. Horwitz SM, Ansell SM, Ai WZ, et al. NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. J Natl Compr Canc Netw
2018;16:123-35. DOI PubMed
53. Jaccard A, Gachard N, Marin B, et al; GELA and GOELAMS Intergroup. Efficacy of L-asparaginase with methotrexate and
dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Blood 2011;117:1834-9. DOI
54. Jaccard A, Suarez F, Delmer A, et al. A prospective phase II trial of an L-asparaginase containing regimen in extra nodal NK/T-cell
lymphoma. Hematol Oncol 2013;31:129. DOI
55. Li X, Cui Y, Sun Z, et al. DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized
controlled, multicenter, open-label study in China. Clin Cancer Res 2016;22:5223-8. DOI PubMed
56. Yhim HY, Kim JS, Mun YC, et al; Consortium for Improving Survival of Lymphoma Study. Clinical outcomes and prognostic factors
of up-front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma. Biol Blood Marrow
Transplant 2015;21:1597-604. DOI
57. Kharfan-Dabaja MA, Kumar A, Ayala E, et al. Clinical Practice recommendations on indication and timing of hematopoietic cell
transplantation in mature T cell and NK/T cell lymphomas: an International Collaborative Effort on Behalf of The Guidelines
Committee of The American Society for blood and marrow transplantation. Biol Blood Marrow Transplant 2017;23:1826-38. DOI
PubMed
58. Song GY, Yoon DH, Suh C, et al. Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by
upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. Bone Marrow
Transplant 2021;56:1205-8. DOI PubMed PMC
59. Kim H, Jeong H, Yamaguchi M, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural
killer/T-cell lymphoma. Blood 2020;136:2548-56. DOI PubMed
60. Kanate AS, DiGilio A, Ahn KW, et al. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma,
nasal type: a CIBMTR analysis. Br J Haematol 2018;182:916-20. DOI PubMed PMC
61. Jung KS, Cho SH, Kim SJ, Ko YH, Kang ES, Kim WS. L-asparaginase-based regimens followed by allogeneic hematopoietic stem
cell transplantation improve outcomes in aggressive natural killer cell leukemia. J Hematol Oncol 2016;9:41. DOI PubMed PMC
62. Takahashi H, Sakai R, Hattori Y, et al. Successful disease control with L-asparaginase monotherapy for aggressive natural killer cell
leukemia with severe hepatic failure. Leuk Lymphoma 2013;54:662-4. DOI PubMed
63. Teshima T, Miyaji R, Fukuda M, Ohshima K. Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large
granular lymphocyte leukaemia. Lancet 1996;347:1124. DOI PubMed
64. Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-
cell neoplasms. Br J Haematol 2005;130:561-7. DOI PubMed
65. Ito T, Makishima H, Nakazawa H, et al. Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell
transplantation. Eur J Haematol 2008;81:107-11. DOI PubMed
66. Hamadani M, Kanate AS, DiGilio A, et al. Allogeneic hematopoietic cell transplantation for aggressive NK cell leukemia. A center for
international blood and marrow transplant research analysis. Biol Blood Marrow Transplant 2017;23:853-6. DOI PubMed PMC
67. Jeong SH, Song HN, Park JS, et al. Allogeneic stem cell transplantation for patients with natural killer/T cell lymphoid malignancy: a
multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transplant 2018;24:2471-8. DOI PubMed
68. Fujimoto A, Ishida F, Izutsu K, et al. Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia. Bone Marrow
Transplant 2021;56:347-56. DOI PubMed
69. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-
associated malignancies. Clin Cancer Res 2013;19:3462-73. DOI PubMed PMC
70. Kataoka K, Miyoshi H, Sakata S, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-
associated lymphomas. Leukemia 2019;33:1687-99. DOI PubMed PMC
71. Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell
lymphoma failing l-asparaginase. Blood 2017;129:2437-42. DOI PubMed
72. Lim JQ, Huang D, Tang T, et al. Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-
killer/T cell lymphoma. Leukemia 2020;34:3413-9. DOI PubMed PMC
73. Li X, Cheng Y, Zhang M, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol 2018;11:15.
DOI PubMed PMC
74. Chan TSY, Li J, Loong F, Khong PL, Tse E, Kwong YL. PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing L-
asparaginase: efficacy and safety. Ann Hematol 2018;97:193-6. DOI PubMed
75. Li J, Tao R, Fan L, et al. Sintilimab for relapsed/refractory (r/r) extranodal NK/T cell lymphoma (ENKTL): extended follow-up on the
multicenter, single-arm phase II trail (ORIENT-4). J Clin Oncol 2020;38:8050. DOI
76. Kim SJ, Lim JQ, Laurensia Y, et al. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-
label phase 2 study. Blood 2020;136:2754-63. DOI PubMed
77. Gao Y, Huang H, Wang X, et al. Anti-PD-1 antibody (Sintilimab) plus histone deacetylase inhibitor (Chidamide) for the treatment of
refractory or relapsed extranodal natural killer/T cell lymphoma, nasal type (r/r-ENKTL): preliminary results from a prospective,
multicenter, single-arm, phase Ib/II trial (SCENT). Blood 2020;136:39-40. DOI
78. Cai J, Liu P, Huang H, et al. Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for